The BPMUF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BPMUF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BPMUF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View BPMUF Detailed Price Forecast - CNN Money | View BPMUF Detailed Summary - Google Finance | ||
View BPMUF Detailed Summary - Yahoo! Finance | View BPMUF Stock Research & Analysis - Zacks.com |
View BPMUF Trends & Analysis - Trade-Ideas | View BPMUF Major Holders - Barrons | ||
View BPMUF Call Transcripts - NASDAQ | View BPMUF Breaking News & Analysis - Seeking Alpha | ||
View BPMUF Annual Report - CompanySpotlight.com | View BPMUF OTC Short Report - OTCShortReport.com | ||
View BPMUF Fundamentals - TradeKing | View BPMUF SEC Filings - Bar Chart | ||
View Historical Prices for BPMUF - The WSJ | View Performance/Total Return for BPMUF - Morningstar | ||
View the Analyst Estimates for BPMUF - MarketWatch | View the Earnings History for BPMUF - CNBC | ||
View the BPMUF Earnings - StockMarketWatch | View BPMUF Buy or Sell Recommendations - MacroAxis | ||
View the BPMUF Bullish Patterns - American Bulls | View BPMUF Short Pain Metrics - ShortPainBot.com |
View BPMUF Stock Mentions - StockTwits | View BPMUF Stock Mentions - PennyStockTweets | ||
View BPMUF Stock Mentions - Twitter | View BPMUF Investment Forum News - Investor Hub | ||
View BPMUF Stock Mentions - Yahoo! Message Board | View BPMUF Stock Mentions - Seeking Alpha |
View Insider Transactions for BPMUF - SECform4.com | View Insider Transactions for BPMUF - Insider Cow | ||
View BPMUF Major Holdings Summary - CNBC | View Insider Disclosure for BPMUF - OTC Markets | ||
View Insider Transactions for BPMUF - Yahoo! Finance | View Institutional Holdings for BPMUF - NASDAQ |
View BPMUF Stock Insight & Charts - FinViz.com | View BPMUF Investment Charts - StockCharts.com | ||
View BPMUF Stock Overview & Charts - BarChart | View BPMUF User Generated Charts - Trading View |
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
Posted on Monday April 08, 2024
Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial p
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
Posted on Wednesday April 03, 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the US Food and Drug Administration (FDA) approved ZEVTERA® (ceftobiprole medocaril sodium for injection), for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), i
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Posted on Sunday March 10, 2024
Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
Posted on Monday February 12, 2024
Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidanceAddition of three new anti-infective assets to clinical portfolio, including phase-3-ready antifungal fosmanogepixStrong cash and restricted cash position of CHF 64.3 million, after fully absorbing investments into portfolio expansion and accelerated debt reduction FY 2024 guidance: